ICON-1 is under clinical development by Iconic Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ICON-1’s likelihood of approval (LoA) and phase transition for Choroidal Neovascularization took place on 04 Aug 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ICON-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ICON-1 overview

ICON-1 is under development for the treatment of wet age-related macular degeneration, choroidal neovascularization. It is administered as an intravitreal injection. The drug candidate is all-human chimeric, IgG-like homodimeric protein composed of a targeting domain (mutated, inactive factor VIIa) fused to an effector domain (Fc portion of IgG) via an intact hinge region. The drug candidate by acts by targeting the tissue factor. The drug candidate was under development for the treatment of various forms of cancer including melanoma, prostate cancer, uterine papillary serous carcinoma and ovarian cancer and uveal melanoma.

Iconic Therapeutics overview

Iconic Therapeutics is a biopharmaceutical company. It provides translation of scientific insight into breakthrough medicines. The company offers development of tissue factor in inflammation, angiogenesis, and metastasis that led to develop new approach to retinal disease and cancer. It also provides ICON-1 product that offers novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of acute vision loss in AMD. Iconic Therapeutics’ product is used in treatments in course of infections causing blindness. The company offers its products across the US. Iconic Therapeutics is headquartered in San Francisco, California, the US.

Quick View ICON-1 LOA Data

Report Segments
  • Innovator
Drug Name
  • ICON-1
Administration Pathway
  • Intravitreal
Therapeutic Areas
  • Oncology
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.